BridgeBio (BBIO) Corporate presentation summary

Business model and strategy

• Focuses on targeting genetic diseases at the source for higher probability of success from day one.

• Employs rapid, decentralized R&D decisions with affiliate autonomy.

• Utilizes variable costs, shared infrastructure, diversified financing, and asset-level incentives.

• Built a sustainable, high-velocity engine impacting over 10,000 individuals and supporting >70 active trials.

• Leverages lean teams to advance medicines efficiently, with small team sizes for each program.

Pipeline and portfolio

• Portfolio includes approved and late-stage assets: Attruby (acoramidis), Nulibry, TRUSELTIQ, BBP-418, encaleret, infigratinib, and BBP-812.

• Over 17 programs across rare genetic and oncology indications, with >$20B market opportunity.

• Three medicines approved; >70 active trials and >35 academic partnerships.

• Late-stage assets show strong efficacy and safety, with several first-in-class or best-in-class designations.

Financial position and commercialization

• Holds $1.7B in cash to support three potential US launches by mid-2027.

• Centralized commercial model enables cost synergies and tailored launch strategies for rare diseases.

• Proven commercial infrastructure established, leveraging experience from prior launches.